Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Laudani, A. [1 ]
Savio, G. [1 ]
Leonardi, V. [1 ]
Palmisano, V. [1 ]
Tartaglia, L. [1 ]
Manuguerra, G. [1 ]
Pepe, A. [1 ]
Alu, M. [1 ]
Usset, A. [1 ]
Agostara, B. [1 ]
机构：
[1] PO M Ascoli ARNAS Civico, Med Oncol Unit, Dept Oncol, Palermo, Italy
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：6 / 6
页数：1
相关论文
共 50 条
  • [31] Phase II multicenter study of capecitabine plus oxaliplatin (XELOX) sequentially followed by capecitabine and irinotecan (XELIRI) in first-line therapy for metastatic colorectal cancer (MCRC)
    Cassinello, J.
    Alvarez, J. V.
    Garcia-Lopez, M. J.
    Pujol, E.
    Colmenarejo, A.
    De Segovia, F.
    Marcos, F.
    Filipovich, E.
    EJC SUPPLEMENTS, 2005, 3 (02): : 199 - 200
  • [32] Capecitabine and oxaliplatin (XELOX) as first line treatment for patients with metastatic colorectal cancer (MCRC)
    Karacetin, D.
    Maral, O.
    Yalcyn, B.
    Okten, B.
    Incekara, O.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [33] Capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC): Final safety findings from a phase II trial.
    Patt, YZ
    Liebmann, J
    Diamandidis, D
    Eckhardt, SG
    Javle, M
    Justice, GR
    Keiser, W
    Lee, FC
    Miller, W
    Lin, E
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 270S - 270S
  • [34] Final efficacy and safety findings from a phase II trial of capecitabine (X) plus irinotecan (XELIRI) as first-line treatment for metastatic colorectal cancer (MCRC)
    Patt, Yehuda
    Liebmann, James
    Diamandidis, Dimitrios
    Eckhardt, Gail
    Javle, Milind
    Justice, Glen
    Keiser, Leroy W.
    Lee, Fa-Chyi
    Miller, William
    Lin, Edward
    ANNALS OF ONCOLOGY, 2004, 15 : 88 - 88
  • [35] First-line treatment for metastatic colorectal cancer (MCRC) patients (pts). Results of a randomized phase IIITMO study
    Bajetta, E.
    Di Bartolomeo, M.
    Ferrario, E.
    Beretta, E.
    Rabbi, C.
    Isa, L.
    Barone, C.
    Lo, S.
    Zilembo, Vullo N.
    ANNALS OF ONCOLOGY, 2005, 16 : 48 - 48
  • [36] Efficacy and safety of bevacizumab in combination with irinotecan and capecitabine in first-line treatment of metastatic colorectal cancer
    Jungic, Sasa
    Tubic, Biljana
    Gajanin, Radoslav
    Gojkovic, Zdenka
    Rakita, Ivanka
    VOJNOSANITETSKI PREGLED, 2017, 74 (03) : 249 - 255
  • [37] Encouraging results from a phase I study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with metastatic colorectal cancer (MCRC)
    Maroun, J.
    Jonker, D.
    Cripps, C.
    Goel, R.
    Lister, D.
    Chiritescu, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [38] EFFICACY OF BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY WITH IRINOTECAN AND CAPECITABINE (XELIRI) IN FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Ocvirk, J.
    Rebersek, M.
    Boc, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [39] Randomised phase III trial comparing irinotecan plus capecitabine (XELIRI Regimen) vs. irinotecan, 5-Fu and folinic acid (Saltz regimen) as first-line treatment in patients (PTS) with metastatic colorectal cancer (MCRC)
    Munoz, Alberto
    Salud, Antonieta
    Garcia Giron, Carlos
    Murias, Adolfo
    Burillo, Miguel A.
    Arizcun, Alberto
    Gutierrez, David
    Pujol, Eduardo
    ANNALS OF ONCOLOGY, 2006, 17 : 120 - 120
  • [40] Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer - Reply
    Fuchs, Charles S.
    Marshall, John
    Barrueco, Jose
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1908 - 1909
12345